> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-204/
- Published: 2018-11-18T12:00:00.000Z
- Updated: 2026-09-15T00:45:24.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5142856

[**Annual Report on Post Marketing Requirements/Commitments**](https://www.fdaweb.com/annual-report-on-post-marketing-requirements-commitments/)  
*Federal Register* notice: FDA announces the availability of its annual report entitled “Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and Commitments.” 11/16/2018

[**Consumer Reps Needed for Advisory Committees**](https://www.fdaweb.com/consumer-reps-needed-for-advisory-committees/)  
*Federal Register* notice: FDA seeks consumer organizations interested in participating in the selection of voting and nonvoting consumer representatives to serve on its advisory committees or panels. 11/16/2018

[**FDA Posts PMA, HDE Approval Notices**](https://www.fdaweb.com/fda-posts-pma-hde-approval-notices/)  
*Federal Register* notice: FDA publishes a list of PMAs and humanitarian device exemption applications that have been recently approved. 11/16/2018

[**FDA Public Meetings on e-Adverse Event Reports**](https://www.fdaweb.com/fda-public-meetings-on-e-adverse-event-reports/)  
*Federal Register* notice: FDA announces three public meetings entitled “Electronic Submission of Adverse Event Reports to FDA Adverse Event Reporting System (FAERS) Using International Council for Harmonization (ICH) E2B(R3) Standards.” 11/15/2018

[**Proposal to Allow Informed Consent Exceptions**](https://www.fdaweb.com/proposal-to-allow-informed-consent-exceptions/)  
*Federal Register* proposed rule: FDA proposes to amend its regulations to implement a provision of the 21st Century Cures Act that would allow an exception from the requirement to obtain informed consent when a clinical investigation poses no more than minimal risk to the human subject. 11/15/2018

[**Workshop on Drug-caused Blood Pressure Effects** ](https://www.fdaweb.com/workshop-on-drug-caused-blood-pressure-effects/)*Federal Register* notice: FDA announces a 2/4 public workshop entitled “Evaluating the Pressor Effects of Drugs.” 11/14/2018

[**Guide on Nonmetastatic, Castration-Resistant Prostate Cancer**](https://www.fdaweb.com/guide-on-nonmetastatic-castration-resistant-prostate-cancer/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Nonmetastatic, Castration-Resistant Prostate Cancer: Considerations for Metastasis-Free Survival Endpoint in Clinical Trials.” 11/14/2018

[**Info Collection on Device Fees for Small Businesses**](https://www.fdaweb.com/info-collection-on-device-fees-for-small-businesses/)  
*Federal Register* notice: FDA seeks comments on an information collection extension on a guidance for “Medical Device User Fee Small Business Qualification and Certification.” 11/13/2018

[**Info Collection on IND Sponsor Surveys**](https://www.fdaweb.com/info-collection-on-ind-sponsor-surveys/)  
*Federal Register* notice: FDA submits to OMB a new information collection entitled “Surveys and Interviews With Investigational New Drug (IND) Sponsors To Assess Current Communication Practices With FDA Review Staff Under the Sixth Authorization of the Prescription Drug User Fee Act (PDUFA VI).” 11/13/2018